Global Conjunctivitis Drugs Market Professional Survey Report 2019

Conjunctivitis, or pink eye, is inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid due to numerous causes the most common being bacterial infection. The condition is self-limiting, but in some cases results in kerato-conjunctivitis, which results in blurred vision. The viral and bacterial conjunctivitis results in highly infectious watery discharge which is extremely contagious.
The market for conjunctivitis is growing at a moderate rate. The growth factors for the growth of global conjunctivitis drugs market are rise in hygiene and awareness, growing expenditure on health, greater exposure to allergens and infective agents, the contagious nature of the disease etc. However the market is restrained by many factors such as the self-limiting nature of the disease, off label drug use,

The global Conjunctivitis Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Conjunctivitis Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Conjunctivitis Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Conjunctivitis Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Conjunctivitis Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Akorn Pharmaceuticals
Alcon/ Novartis
Allergan
Bausch & Lomb
Valeant Pharmaceuticals
Merck
Actavis
Pfizer

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Antibiotics
Mast Cell Stabilizers
Steroids
Others

Segment by Application
Hospitals
Self-Administered